Athersys, Inc. - Common Stock (NQ:ATHX)

N/A UNCHANGED

Last Price Updated: 4:00 PM EDT, Oct 17, 2023 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Athersys, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >

The Daily Biotech Pulse: Dicerna Slips On Data, Novavax Tightlipped On US Vaccine Approval, Adagio IPO ↗

August 06, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 5) Alkermes plc (NASDAQ: ALKS)...

Via Benzinga

Week Ahead In Biotech (May 2-8): ChemoCentryx Adcom, Ophthalmology Conference Presentations, Earnings Deluge ↗

May 01, 2021

Biopharma stocks experienced volatility in the week ended April 30, as stocks reacted to earnings, data readouts and a handful of FDA decisions. Earnings prints from big name...

Via Benzinga

The Week Ahead In Biotech (Aug. 8-14): Jazz Pharma FDA Decision, Earnings Deluge and IPOs In The Spotlight ↗

August 08, 2021

Biopharma stocks ended higher for the week ending Aug. 6, as the sector latched on to the optimism that was evident in the broader markets. Earnings continued to flow in,...

Via Benzinga

12 Health Care Stocks Moving In Friday's After-Market Session ↗

August 06, 2021

Gainers Nuwellis (NASDAQ:NUWE) shares in...

Via Benzinga

12 Health Care Stocks Moving In Friday's Pre-Market Session ↗

August 06, 2021

Gainers Applied Molecular (NASDAQ:AMTI) shares increased by 19.38% to $35.54 during Friday's pre-market session. The market value of their outstanding shares is at $1....

Via Benzinga

Athersys Partner HEALIOS K.K. Announces Positive Topline Results of MultiStem for Acute Respiratory Distress Syndrome in the ONE-BRIDGE Study

August 06, 2021

From Athersys, Inc.

Via Business Wire

Athersys and HEALIOS K.K. Announce Advancement of Their MultiStem Commercial Partnership

August 05, 2021

From Athersys, Inc. and HEALIOS K.K.

Via Business Wire

Athersys to Host Second Quarter Financial Results Call

July 13, 2021

From Athersys, Inc.

Via Business Wire

Stocks That Hit 52-Week Lows On Wednesday ↗

June 30, 2021

During Wednesday's morning session, 29 stocks hit new 52-week lows. Points of Interest: The largest company by market cap to set a new 52-week low was CoStar Gr (...

Via Benzinga

The Daily Biotech Pulse: Ardelyx Sinks On Regulatory Setback, AnPac Issues Positive Preannouncement, European Nod For Myovant, HCW Biologics Debuts On Wall Street ↗

July 20, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 19) Cytokinetics, Incorporated...

Via Benzinga

The Daily Biotech Pulse: Moderna To Join S&P 500 Index, Thumbs Down For FibroGen's Anemia Drug, Corvus Shelves COVID Study ↗

July 16, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 15) IVERIC bio, Inc. (NASDAQ:...

Via Benzinga

Topics Stocks

The Daily Biotech Pulse: Spero Spikes On Pfizer Investment, FDA Nod For Jazz, Orchard Signs Licensing Deal, Acumen Pharma Debuts ↗

July 01, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 30) Ambrx Biopharma Inc. (NYSE...

Via Benzinga

New Publication Provides Further Clarity of MultiStem's Mechanism of Action on Modulating the Inflammatory Response in Critical Care Indications

June 30, 2021

From Athersys, Inc.

Via Business Wire

12 Health Care Stocks Moving In Friday's After-Market Session ↗

May 14, 2021

Gainers Evaxion Biotech (NASDAQ:EVAX) sha...

Via Benzinga

Stocks That Hit 52-Week Lows On Monday ↗

May 10, 2021

Monday morning saw 78 companies set new 52-week lows. Intriguing Points: The largest company by market cap to set a new 52-week low was Rocket Companies (NYSE:RKT)....

Via Benzinga

The Daily Biotech Pulse: Minerva, InflaRx Report Positive Data Readouts, Lucira COVID-19 Test Kit Available On Amazon, Decision Day For Heron ↗

May 12, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 11) HOOKIPA Pharma Inc. (NASDAQ...

Via Benzinga

The Daily Biotech Pulse: FDA Authorizes Pfizer-BioNTech COVID-19 Vaccine For Adolescents, Lilly Strikes R&D Collaboration, Vaccine Stocks Novavax, Inovio Sink On Earnings ↗

May 11, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 10) AbbVie Inc. (NYSE: ABBV) -...

Via Benzinga

The Daily Biotech Pulse: Split Verdict For Chemocentryx, NKarta-CRISPR In Cell Therapy Collaboration, Orphazyme's Clinical Trial Setback, 2 IPOs ↗

May 07, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 6) GT Biopharma, Inc. (NASDAQ:...

Via Benzinga

Athersys (ATHX) Q1 2021 Earnings Call Transcript ↗

May 07, 2021

ATHX earnings call for the period ending March 31, 2021.

Via The Motley Fool

Topics Earnings

Athersys Reports First Quarter 2021 Results

May 06, 2021

From Athersys, Inc.

Via Business Wire

Athersys to Present at the Bank of America Virtual Healthcare Conference on May 12

April 28, 2021

From Athersys Inc.

Via Business Wire

Athersys to Host First Quarter Financial Results Call

April 13, 2021

From Athersys, Inc.

Via Business Wire

The Daily Biotech Pulse: Merck's Keytruda Snags Another FDA Approval, Moderna Slips On Revenue Miss, Chemocentryx Adcom ↗

May 06, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 5) AbbVie Inc. (NYSE: ABBV)...

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 9 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.